JAK2 and diabetes mellitus: Experimental studies of the JAK1/JAK2 inhibitor ruxolitinib in the LEW.1WR1 rat model demonstrate that initiating administration prior to the onset of insulitis and maintaining treatment throughout the disease progression completely prevents diabetes development (40).